(Q44764112)

6 December 2017

Pharmacokinetics of rifapentine at 600, 900, and 1,200 mg during once-weekly tuberculosis therapy (English)

1 reference

6 December 2017

1 reference

1 reference

1 reference

Marc Weiner

1

1 reference

6 December 2017

Naomi Bock

2

1 reference

6 December 2017

Charles A Peloquin

3

1 reference

6 December 2017

William J Burman

4

1 reference

6 December 2017

Awal Khan

5

1 reference

6 December 2017

Andrew Vernon

6

1 reference

6 December 2017

Zhen Zhao

7

1 reference

6 December 2017

Stephen Weis

8

1 reference

6 December 2017

Timothy R Sterling

9

1 reference

6 December 2017

Katherine Hayden

10

1 reference

6 December 2017

Stefan Goldberg

11

1 reference

6 December 2017

Tuberculosis Trials Consortium

12

1 reference

6 December 2017

language of work or name

English

0 references

publication date

12 February 2004

1 reference

American Journal of Respiratory and Critical Care Medicine

6 December 2017

1 reference

6 December 2017

169

1 reference

6 December 2017

1191-1197

1 reference

6 December 2017

11

1 reference

American Thoracic Society/Centers for Disease Control and Prevention/Infectious Diseases Society of America

6 December 2017

1 reference

https://api.crossref.org/works/10.1164%2FRCCM.200311-1612OC

Rifapentine and isoniazid once a week versus rifampicin and isoniazid twice a week for treatment of drug-susceptible pulmonary tuberculosis in HIV-negative patients: a randomised clinical trial

21 January 2018

1 reference

https://api.crossref.org/works/10.1164%2FRCCM.200311-1612OC

Antituberculosis activity of once-weekly rifapentine-containing regimens in mice. Long-term effectiveness with 6- and 8-month treatment regimens

21 January 2018

1 reference

https://api.crossref.org/works/10.1164%2FRCCM.200311-1612OC

A prospective, randomized, double-blind study of the tolerability of rifapentine 600, 900, and 1,200 mg plus isoniazid in the continuation phase of tuberculosis treatment

21 January 2018

1 reference

https://api.crossref.org/works/10.1164%2FRCCM.200311-1612OC

Pneumococcal meningitis in the intensive care unit: prognostic factors of clinical outcome in a series of 80 cases

21 January 2018

1 reference

https://api.crossref.org/works/10.1164%2FRCCM.200311-1612OC

Bactericidal activity in vitro of various rifamycins against Mycobacterium avium and Mycobacterium tuberculosis

21 January 2018

1 reference

https://api.crossref.org/works/10.1164%2FRCCM.200311-1612OC

Activity of rifapentine and its metabolite 25-O-desacetylrifapentine compared with rifampicin and rifabutin against Mycobacterium tuberculosis, Mycobacterium africanum, Mycobacterium bovis and M. bovis BCG.

21 January 2018

1 reference

https://api.crossref.org/works/10.1164%2FRCCM.200311-1612OC

Low isoniazid concentrations and outcome of tuberculosis treatment with once-weekly isoniazid and rifapentine

21 January 2018

1 reference

https://api.crossref.org/works/10.1164%2FRCCM.200311-1612OC

Clinical significance of esterases in man.

21 January 2018

1 reference

https://api.crossref.org/works/10.1164%2FRCCM.200311-1612OC

Pharmacogenomics: translating functional genomics into rational therapeutics

21 January 2018

1 reference

https://api.crossref.org/works/10.1164%2FRCCM.200311-1612OC

Determination of minimal inhibitory concentrations of antituberculosis drugs by radiometric and conventional methods

21 January 2018

1 reference

https://api.crossref.org/works/10.1164%2FRCCM.200311-1612OC

Comparison of activities of rifapentine and rifampin against Mycobacterium tuberculosis residing in human macrophages

21 January 2018

1 reference

https://api.crossref.org/works/10.1164%2FRCCM.200311-1612OC

10.1164/RCCM.200311-1612OC

21 January 2018

Identifiers

DOI

1 reference

6 December 2017

1 reference